📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
58 announcements match the current filters (relevance ≥ 5).
Fortis Healthcare Subsidiary Tax Demand Reduced to ₹61.48 Cr from ₹117.04 Cr
Fortis Healthcare's wholly-owned subsidiary, Fortis Hospitals Limited, has successfully processed a rectification application with the Income Tax Authority for Assessment Year 2024-25. The initial tax demand of INR 117.04 Crores has been significantly reduced to INR 61.48 Crores. This reduction of approximately INR 55.56 Crores represents a positive outcome in the company's tax litigation, lowering potential cash outflows and liabilities.
Key Highlights
Income Tax Authority reduced the tax demand for Fortis Hospitals Limited for AY 2024-25.
The demand was lowered from INR 117.04 Crores to INR 61.48 Crores following a rectification application.
The reduction represents a total saving of INR 55.56 Crores in tax liability for the subsidiary.
The order was passed under Section 154 read with Section 143(3) of the Income Tax Act, 1961.
The rectification follows an earlier communication dated March 28, 2026, regarding the initial demand.
👀 What to Watch
Investors should view this as a positive development as it clarifies and reduces a significant contingent liability. No immediate action is required, but it demonstrates effective management of regulatory and tax disputes.
Fortis Healthcare FY26 PAT Rises 31.5% to ₹1,064 Cr; Recommends ₹1 Dividend
Fortis Healthcare delivered a robust FY26 performance with consolidated revenue increasing 17.3% to ₹9,128 crores and PAT growing 31.5% to ₹1,064 crores. The hospital business led growth with a 19.1% revenue increase, while consolidated EBITDA margins expanded significantly to 22.8% from 20.4%. The company is aggressively expanding its footprint, having added 800 beds in FY26 through acquisitions and brownfield projects, with plans for another 1,800 beds over four years. A dividend of ₹1 per share was recommended, reflecting strong cash flow and fundamental strength.
Key Highlights
Consolidated EBITDA grew 31.3% YoY to ₹2,085 crores with a margin of 22.8%.
Hospital business ARPOB increased by 3.4% to ₹2.51 crores per annum in FY26.
Agilus Diagnostics reported a 23.6% EBITDA margin for FY26, up from 17.7% in FY25.
Net debt-to-EBITDA ratio stood at 1.09x as of March 31, 2026, following strategic acquisitions.
Planned addition of 400+ beds in FY27 across FMRI, Noida, and other key regional clusters.
👀 What to Watch
Investors should maintain a positive outlook given the strong margin expansion and clear growth visibility through the 1,800-bed expansion pipeline. The successful turnaround of the diagnostic business and steady ARPOB growth are key performance drivers to watch.
Fortis Healthcare Recommends ₹1 Dividend and Approves FY26 Audited Financial Results
Fortis Healthcare's Board has recommended a final dividend of ₹1 per equity share (10% of face value) for the financial year 2025-26. The company approved its audited standalone and consolidated financial results for the year ended March 31, 2026, with an unmodified audit opinion. While current operations appear stable, the auditors highlighted ongoing legacy legal issues, including SFIO investigations and Supreme Court oversight regarding transactions prior to 2018. Additionally, the company has appointed new cost auditors and updated its Corporate Social Responsibility policy.
Key Highlights
Recommended a final dividend of ₹1 per equity share (10% of face value) for FY 2025-26.
Statutory auditors B S R & Co. LLP issued an unmodified opinion on the FY26 financial results.
Ongoing SFIO investigation and Supreme Court oversight regarding legacy transactions (pre-2018) remain an 'Emphasis of Matter'.
Appointed M/s Jitender, Navneet & Co. as Cost Auditors for the 2026-27 financial year.
The Board meeting concluded after 10 hours of deliberation, approving the updated CSR policy.
👀 What to Watch
Investors should welcome the dividend payout and the clean audit opinion on current financials, but must continue to monitor the legacy legal proceedings mentioned in the auditor's report.
Fortis Healthcare Recommends ₹1 Dividend; Reports FY26 Audited Results with Unmodified Opinion
Fortis Healthcare's Board has recommended a final dividend of ₹1 per equity share (10% of face value) for the financial year 2025-26. The company successfully concluded its FY26 audit with an unmodified opinion from statutory auditors B S R & Co. LLP, signaling financial reporting reliability. However, the report highlights ongoing legacy legal challenges, including SFIO investigations into pre-2018 transactions and Supreme Court-directed scrutiny of RHT Health Trust dealings. The company also appointed M/s Jitender, Navneet & Co. as cost auditors for the upcoming fiscal year.
Key Highlights
Recommended a final dividend of ₹1 per equity share (10% of ₹10 face value) for FY 2025-26.
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results for FY ended March 31, 2026.
Ongoing SFIO investigation continues regarding alleged improper transactions and non-compliances originating prior to the 2018 board reconstitution.
The Supreme Court's September 2022 order regarding a potential forensic audit of RHT Health Trust transactions remains a key legal watchpoint.
M/s Jitender, Navneet & Co. appointed as Cost Auditors for FY 2026-27 to ensure regulatory compliance.
👀 What to Watch
Investors should welcome the dividend and the clean audit report as signs of operational stability. However, long-term positions should be weighed against the potential outcomes of the ongoing SFIO and Supreme Court-related legal proceedings.
Fortis Healthcare Recommends ₹1 Final Dividend; FY26 Audited Results Approved
Fortis Healthcare's Board has recommended a final dividend of ₹1 per equity share (10% of face value) for the financial year 2025-26. The company approved its audited standalone and consolidated financial results for the year ended March 31, 2026, with an unmodified audit opinion. While the dividend is a positive signal, auditors highlighted ongoing legal matters including SFIO investigations and Supreme Court proceedings related to historical transactions. The company also appointed M/s Jitender, Navneet & Co. as Cost Auditors for FY 2026-27.
Key Highlights
Recommended a final dividend of ₹1 per equity share of face value ₹10 each for FY 2025-26.
Audited financial results for the quarter and year ended March 31, 2026, approved with an unmodified audit opinion.
Appointment of M/s Jitender, Navneet & Co. as Cost Auditors for the financial year 2026-27.
Auditors included an 'Emphasis of Matter' regarding ongoing SFIO investigations into pre-2018 transactions.
The Board Meeting lasted approximately 10 hours, concluding at 19:35 IST on May 22, 2026.
👀 What to Watch
Investors should view the dividend as a sign of financial stability, though the yield remains modest. Continue to monitor the legal developments mentioned in the audit report regarding the SFIO and RHT Health Trust matters.
Fortis Healthcare Recommends ₹1 Dividend and Approves FY26 Audited Financial Results
Fortis Healthcare has recommended a final dividend of ₹1 per share (10% of face value) for the financial year 2025-26. The Board approved the audited financial results for the year ended March 31, 2026, with statutory auditors providing an unmodified opinion. The company also appointed M/s Jitender, Navneet & Co. as cost auditors for FY 2026-27. However, the audit report continues to highlight significant legacy legal issues, including an ongoing SFIO investigation and Supreme Court observations regarding RHT Health Trust.
Key Highlights
Recommended a final dividend of ₹1 per equity share (10% of face value) for FY 2025-26.
Statutory auditors BSR & Co. LLP issued an unmodified opinion on the consolidated financial results for FY26.
Appointed M/s Jitender, Navneet & Co. as Cost Auditors for the 2026-27 financial year.
Audit report includes an 'Emphasis of Matter' regarding ongoing SFIO investigations into pre-2018 transactions.
The Board meeting concluded after 10 hours of deliberation on financial results and corporate policies.
👀 What to Watch
While the dividend is a positive sign of stability, investors should remain cautious and monitor the ongoing legal and regulatory investigations highlighted in the audit report. The resolution of legacy issues regarding the SFIO and RHT Health Trust remains a key long-term monitorable.
Fortis Healthcare FY26 PAT Jumps 31.5% to INR 1,064 Cr; Recommends INR 1 Dividend
Fortis Healthcare delivered a robust performance in FY26, with consolidated revenue growing 17.3% to INR 9,128 Cr and PAT rising 31.5% to INR 1,064 Cr. The hospital business, contributing 85% of total revenue, saw a 19.1% growth driven by a 15% increase in occupied beds and strong growth in high-value specialties like Robotic Surgeries. The diagnostics arm, Agilus, reported a significant EBITDA margin improvement to 23.6% from 17.7% in the previous year. The company also expanded its network by adding approximately 500 beds through strategic acquisitions in Bengaluru and Jalandhar.
Key Highlights
Consolidated FY26 Revenue reached INR 9,128 Cr, up 17.3% YoY, with Operating EBITDA margins expanding to 22.8%.
Hospital business revenue grew 19.1% in FY26, supported by a 17% YoY increase in occupied beds in Q4.
Diagnostics business EBITDA surged 44.7% in FY26, with margins improving to 23.6% from 17.7% YoY.
Net debt stood at INR 2,334 Cr (1.09x EBITDA) following the acquisition of People Tree and Shrimann Hospitals.
The Board of Directors recommended a final dividend of INR 1 per share (10% of face value).
👀 What to Watch
Investors should maintain a positive outlook given the strong margin expansion across both hospital and diagnostic segments and the successful execution of inorganic growth strategies. Monitor the integration of newly acquired hospitals and the progress of brownfield expansion plans for continued growth momentum.
Fortis Healthcare FY26 PAT Up 31.5% to INR 1,064 Cr; INR 1 Dividend Declared
Fortis Healthcare reported a robust performance for FY26, with consolidated revenues growing 17.3% to INR 9,128 Cr and PAT increasing 31.5% to INR 1,064 Cr. The hospital business, which now contributes 85% of total revenue, saw a 19.1% revenue growth driven by a 15% increase in occupied beds and improved ARPOB of INR 2.51 Cr. The diagnostics arm, Agilus, also showed significant margin improvement, with EBITDA margins rising to 23.6% for the full year. The company continued its expansion strategy, adding approximately 500 beds through acquisitions in Bengaluru and Jalandhar.
Key Highlights
Consolidated FY26 Revenue grew 17.3% YoY to INR 9,128 Cr with PAT rising 31.5% to INR 1,064 Cr.
Operating EBITDA margins expanded significantly to 22.8% in FY26 from 20.4% in FY25.
Hospital business ARPOB increased to INR 2.56 Cr in Q4 FY26, while international patient revenue reached INR 639 Cr for the year.
Board recommended a dividend of INR 1 per share, representing 10% of the face value.
Net debt stood at INR 2,334 Cr (1.09x Net Debt/EBITDA) following the acquisition of People Tree and Shrimann Hospitals.
👀 What to Watch
Investors should take note of the strong margin expansion and the successful execution of the inorganic growth strategy. The steady growth in high-value specialties and international patient revenue reinforces a positive outlook for the stock.
Fortis Healthcare Approves FY26 Audited Results; Recommends ₹1 Final Dividend
Fortis Healthcare's Board has approved the audited financial results for the fiscal year ending March 31, 2026, with the statutory auditor providing an unmodified opinion. The company recommended a final dividend of ₹1 per equity share, representing 10% of the face value of ₹10. Additionally, M/s Jitender, Navneet & Co. has been appointed as the Cost Auditor for the upcoming financial year 2026-27. While the financial reports are clean, the auditors highlighted ongoing regulatory investigations by the SFIO and legal matters involving the Supreme Court regarding past promoter transactions.
Key Highlights
Recommended a final dividend of ₹1 per equity share (10% of face value) for FY 2025-26.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Statutory auditors B S R & Co. LLP issued an unmodified opinion on the financial statements.
Appointed M/s Jitender, Navneet & Co. as Cost Auditors for the Financial Year 2026-27.
Auditors included an 'Emphasis of Matter' regarding ongoing SFIO investigations into past promoter-related transactions.
👀 What to Watch
Investors should take confidence in the dividend recommendation and the unmodified audit opinion as signs of financial stability. However, it is prudent to continue monitoring the legal developments regarding the SFIO investigation and Supreme Court proceedings mentioned in the audit notes.
Fortis Healthcare Recommends Final Dividend of ₹1 Per Share for FY 2025-26
Fortis Healthcare's board has recommended a final dividend of ₹1 per equity share, representing 10% of the face value for the financial year 2025-26. The company approved its audited financial results for the year ended March 31, 2026, which received an unmodified opinion from statutory auditors B S R & Co. LLP. While the dividend signals a return to shareholders, the auditor's report continues to highlight ongoing regulatory investigations by the SFIO and the Supreme Court regarding historical transactions. The dividend payment is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of ₹1 per equity share (10% of ₹10 face value) for FY 2025-26.
Audited financial results for the year ended March 31, 2026, approved with an unmodified audit opinion.
Auditor's report includes an 'Emphasis of Matter' regarding ongoing SFIO and Supreme Court investigations into past transactions.
Appointment of M/s Jitender, Navneet & Co. as Cost Auditors for the 2026-27 financial year.
The board meeting lasted approximately 10 hours, concluding with the approval of financial results and CSR policies.
👀 What to Watch
Investors should view the dividend as a positive sign of operational stability, though the yield remains modest. Continue to monitor the legal developments regarding the SFIO and Supreme Court investigations mentioned in the audit report as they represent long-term contingent risks.
Fortis Healthcare Recommends ₹1 Final Dividend; Approves FY26 Audited Financial Results
Fortis Healthcare's Board has approved the audited financial results for the fiscal year ending March 31, 2026, and recommended a final dividend of ₹1 per share (10% of face value). The statutory auditors issued an unmodified opinion on the results, although they included an 'Emphasis of Matter' regarding legacy legal issues. These issues involve ongoing SFIO investigations into transactions prior to 2018 and Supreme Court proceedings related to the RHT Health Trust. The company continues to cooperate with regulatory authorities and maintains that any further financial impact is not expected to be material.
Key Highlights
Recommended a final dividend of ₹1 per equity share (10% of face value) for FY 2025-26.
Statutory auditors B S R & Co. LLP issued an unmodified audit opinion for the financial year ended March 31, 2026.
Ongoing SFIO investigation continues regarding alleged improper transactions originating prior to the 2018 board reconstitution.
The Supreme Court is considering the appointment of forensic auditors to analyze transactions between the company and RHT Health Trust.
Appointed M/s Jitender, Navneet & Co. as Cost Auditors for the financial year 2026-27.
👀 What to Watch
Investors should monitor the detailed financial performance metrics in the full report while noting that legacy legal overhangs remain a persistent but largely provisioned risk. The dividend recommendation signals stable cash flows despite ongoing regulatory scrutiny.
Fortis Promoter NTK's Case Against Daiichi: Tokyo Court Judgment Set for Sept 10, 2026
Northern TK Venture Pte Ltd (NTK), the promoter shareholder of Fortis Healthcare and a subsidiary of IHH Healthcare, is engaged in material litigation against Daiichi Sankyo in the Tokyo District Court. The court has concluded preparatory and oral proceedings regarding NTK's claim. A final judgment is now scheduled to be delivered on September 10, 2026. This legal battle is a critical component of the long-standing issues surrounding IHH's acquisition of Fortis and the pending mandatory open offer.
Key Highlights
Tokyo District Court has concluded oral proceedings in the litigation filed by NTK against Daiichi Sankyo.
The court is scheduled to announce its judgment on September 10, 2026.
The litigation is linked to the mandatory open offer for an additional 26.10% stake in Fortis Healthcare.
NTK is an indirect wholly-owned subsidiary of IHH Healthcare Berhad, the promoter of Fortis.
👀 What to Watch
Investors should monitor the legal developments as the judgment in September 2026 will be a significant milestone for the completion of the pending open offer. The stock remains sensitive to these legal proceedings which impact the finality of the IHH-Fortis transaction.
Fortis Healthcare Reports Credit Rating Upgrade to AA+ and Timely Servicing of ₹1,550 Cr Debt
Fortis Healthcare has filed its annual disclosure for corporate bonds for the financial year ended March 31, 2026. A key highlight is the credit rating upgrade by CRISIL from AA to AA+ (Stable) for its debt instruments, reflecting improved creditworthiness. The company successfully paid interest totaling approximately ₹130.47 Crore on its ₹1,550 Crore bond issuances. All payments were made on the due date of December 22, 2025, with no history of defaults reported.
Key Highlights
Credit rating upgraded from CRISIL AA to CRISIL AA+ (Stable) on September 1, 2025.
Total outstanding non-convertible securities amount to ₹1,550 Crore across three tranches.
Annual interest payments totaling ₹130.47 Crore were paid on the due date of December 22, 2025.
Reported zero defaults or delays in servicing any debt securities for the financial year.
👀 What to Watch
The credit rating upgrade to AA+ is a positive signal of the company's strengthening balance sheet and operational stability. Investors should view this as a reduction in financial risk, supporting a stable long-term outlook.
Fortis Healthcare Subsidiary Receives INR 149.12 Crore Income Tax Demand
Fortis Healthcare's wholly-owned subsidiary, Fortis Hospitals Limited, has received an assessment order from the Income Tax Authority for the Assessment Year 2021-22. The order raises a significant tax demand totaling INR 149.12 Crores. The company has stated it is currently evaluating all legal options, including filing an appeal or a rectification application against the order. This represents a potential financial liability that could impact the company's cash flows if not successfully contested.
Key Highlights
Income Tax demand of INR 149.12 Crores raised against Fortis Hospitals Limited
The demand pertains to the Assessment Year 2021-22
Assessment order was issued on March 27, 2026, and received by the company on March 31, 2026
Management is exploring legal remedies including appeals and rectification applications
👀 What to Watch
Investors should monitor the company's progress in contesting this demand through appeals. While the amount is substantial, the final impact will depend on the outcome of the litigation process.
Fortis Healthcare Subsidiary Receives INR 117.04 Crore Income Tax Demand
Fortis Healthcare's wholly-owned subsidiary, Fortis Hospitals Limited, has received an Income Tax assessment order for AY 2024-25. The order raises a significant tax demand amounting to INR 117.04 Crores. The company has stated it is currently evaluating legal options, including filing an appeal or a rectification application against the order. This development represents a potential financial liability that could impact the company's cash flows if the demand is upheld.
Key Highlights
Income Tax demand of INR 117.04 Crores raised against subsidiary Fortis Hospitals Limited
The tax demand pertains to Assessment Year (AY) 2024-25
Order was issued by the Income Tax Authority on March 27, 2026
Company is exploring legal remedies including appeals and rectification applications
👀 What to Watch
Investors should monitor the progress of the company's appeal against this tax demand as it represents a significant contingent liability. While the company is contesting the order, any unfavorable final ruling would result in a cash outflow of INR 117.04 Crores.
Fortis Healthcare Shareholders Approve ESOP Scheme 2026 with Over 96% Majority
Fortis Healthcare has received shareholder approval for its new 'Employees Stock Option Scheme 2026' through a postal ballot process. The primary resolution to establish the scheme passed with a 96.59% majority, while extensions of the scheme to employees of subsidiaries and associate companies also received requisite approval. This initiative is designed to align employee interests with long-term shareholder value and improve talent retention across the group. The voting results, finalized on March 18, 2026, indicate strong overall support for the management's incentive plan.
Key Highlights
ESOP Scheme 2026 approved with 65.11 crore votes in favor, representing a 96.59% majority.
Grant of options to subsidiary employees passed with a 96.70% majority (65.18 crore votes).
Resolution for associate company employees received 87.58% approval, with 12.42% of votes cast in dissent.
A total of approximately 67.41 crore valid votes were scrutinized for the primary resolution.
👀 What to Watch
Investors should monitor the specific terms of the ESOP grants as they are announced to evaluate the potential equity dilution and impact on earnings per share (EPS).
Fortis Shareholders Approve ESOP Scheme 2026 with Over 96% Majority
Fortis Healthcare shareholders have approved the implementation of the 'Employees Stock Option Scheme 2026' through a postal ballot. The scheme extends to eligible employees of the company, its subsidiaries, and associate companies to align employee interests with long-term shareholder value. The primary resolution for the company's ESOP was passed with a strong 96.59% majority, while the resolution for associate companies saw a slightly lower but still significant 87.58% approval. This move is aimed at talent retention and performance incentivization across the group.
Key Highlights
Resolution to approve Fortis Healthcare Limited ESOP Scheme 2026 passed with 96.59% votes in favor.
Grant of options to subsidiary employees approved with 96.70% majority (65.19 crore votes).
Grant of options to associate company employees approved with 87.58% majority.
Total valid votes for the main resolution reached 67.41 crore shares across 1,290 ballots.
The resolutions were deemed passed on March 18, 2026, following the conclusion of the e-voting process.
👀 What to Watch
Investors should view this as a standard corporate move to retain and incentivize key talent. Monitor the specific details of the grant size in future filings to assess the potential long-term equity dilution.
Fortis Healthcare Completes Merger of Four Subsidiaries into Fortis Hospitals
Fortis Healthcare has announced that the merger of four of its wholly-owned subsidiaries into Fortis Hospitals Limited (FHsL) became effective on March 1, 2026. The entities absorbed include Fortis Emergency Services, Fortis Cancer Care, Fortis Health Management (East), and Birdie & Birdie Realtors. This consolidation follows the filing of certified NCLT orders from the Delhi and Chandigarh benches with the Registrar of Companies. The move is designed to simplify the corporate structure and enhance operational efficiency across the group.
Key Highlights
Merger of four wholly-owned subsidiaries (FESL, FCCL, FHMEL, and B&B) into Fortis Hospitals Limited is now effective.
The effective date of the Scheme of Arrangement is confirmed as March 1, 2026.
NCLT orders from Delhi and Chandigarh benches were filed via Form INC-28 with the ROC.
The restructuring aims to reduce administrative overheads and streamline the organizational hierarchy.
👀 What to Watch
Investors should view this as a positive administrative cleanup that simplifies the company's complex subsidiary structure. No immediate portfolio changes are necessary as the entities were already 100% owned.
Fortis Healthcare Q3 FY26: EBITDA Jumps 34.8%, Margin Expands to 22.3% Amid Strategic Acquisitions
Fortis Healthcare reported a strong Q3 FY26 with consolidated revenues growing 17.5% YoY to INR 2,265 crores, driven by a 19.4% growth in the hospital segment. Operating EBITDA surged 34.8% to INR 505 crores, reflecting significant margin expansion to 22.3% from 19.4% YoY. While reported PAT dipped to INR 197 crores due to a one-off INR 55 crore labor code expense, operational performance remained robust with ARPOB rising 4.5% to INR 2.56 crores. The company continues its aggressive expansion, recently acquiring People Tree Hospital in Bengaluru for INR 430 crores and adding 750 beds during the year.
Key Highlights
Consolidated EBITDA grew 34.8% YoY to INR 505 crores with margins expanding 290 bps to 22.3%.
Hospital business revenue increased 19.4% to INR 1,938 crores, supported by a 4.5% rise in ARPOB to INR 2.56 crores.
Acquired 125-bedded People Tree Hospital in Bengaluru for INR 430 crores with plans to expand to 300 beds.
Agilus Diagnostics reported a sharp margin improvement to 23.1% from 14.4% in the previous year.
Net debt stands at INR 2,547 crores (1.24x Net Debt/EBITDA) following recent inorganic growth investments.
👀 What to Watch
Investors should focus on the strong operational margin expansion and the successful integration of new acquisitions. The temporary dip in PAT due to labor code provisions is a non-recurring item, making the core business growth trajectory attractive.
Fortis Promoter NTK Amends ₹10,930 Crore Lawsuit Against Daiichi Sankyo in Japan
Northern TK Venture (NTK), the promoter of Fortis Healthcare and a subsidiary of IHH Healthcare, has amended its legal claim against Daiichi Sankyo in the Tokyo District Court. NTK is seeking damages totaling approximately INR 10,930 Crores for losses related to tortious claims and defamation. The latest amendment seeks to prevent Daiichi Sankyo from obstructing future investments or corporate actions in Fortis and Fortis Malar through defamatory statements to SEBI. This legal action follows the successful completion of the mandatory open offers in November 2025.
Key Highlights
NTK filed a petition to amend its claim against Daiichi Sankyo in the Tokyo District Court on February 12, 2026.
The total claim amount for tortious losses stands at INR 109,299,359,054 (approx. INR 10,930 Crores).
The amendment aims to restrain Daiichi Sankyo from obstructing future corporate exercises or share acquisitions in Fortis.
This litigation follows the completion of IHH's mandatory open offers for Fortis and Malar on November 10, 2025.
👀 What to Watch
Investors should monitor the progress of this litigation as it affects the promoter's ability to conduct future corporate actions without interference. While it doesn't impact daily operations, the massive claim amount and the attempt to secure injunctive relief are significant for long-term strategic stability.
